Skip to content

Sharp Kinesitherapie

Active
Private limited company·Activiteiten op het gebied van kinesitherapie· 5 yrs active
Liersesteenweg 6/8 ·2547 Lint, Belgium
KBO/BCE: BE 0767.499.236
Watch Print / PDF
Age5 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Sharp Kinesitherapie is 0.3% (very low). The 2024 annual accounts show equity of €32k and a net result of €-19k. Equity is growing by ~39.7% per year across the filed fiscal years. Its solvency ranks better than 10% of 6559 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.3% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Multiple establishment units +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Signals

1 signal · with evidence
Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 6559 sector peers (2024).
View the sector comparison

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Trust signals

3 signals
More than 3 years active
Founded in 2021, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).

Administrative Flags

0 events
No administrative flags

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€-19k
Working capital€-17k

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 29-08-2025 with the NBB · fiscal year 2024 · micro
€-25k€0€25k€50kOperating result 2022: €3k€3kNet result 2022: €2k€2kOperating result 2023: €62k€62kNet result 2023: €44k€44kOperating result 2024: €-7k€-7kNet result 2024: €-19k€-19k202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~39.7%/year over 3 fiscal years, indicative, assuming unchanged policy.
€0€20k€40k€60k€80k2025: €44k (€42k - €47k)2026: €57k (€54k - €60k)2027: €70k (€67k - €72k)2022: €7k2023: €50k2024: €32k202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 7.1% 66.7%
better than 10% of 6559 sector peers
Net result €-19k €46k
better than 5% of 6553 sector peers
Equity €32k €79k
better than 26% of 6559 sector peers
Gross operating margin €47k €78k
better than 32% of 6561 sector peers
Total assets €450k €154k
better than 85% of 6562 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P10
2022: P7 · n=36572023: P12 · n=53192024: P10 · n=65592022 2024
Stable position over 2022-2024 · n=3657-6559
Net result P5
2022: P11 · n=36552023: P55 · n=53182024: P5 · n=65532022 2024
Stable position over 2022-2024 · n=3655-6553
Equity P26
2022: P11 · n=36572023: P42 · n=53212024: P26 · n=65592022 2024
Improving position over 2022-2024 · n=3657-6559
Gross operating margin P32
2022: P42 · n=36532023: P63 · n=53152024: P32 · n=65612022 2024
Stable position over 2022-2024 · n=3653-6561
Describes the position versus peers, not a forecast.
EBITDA
€19k
-79.1% 22-24
Net profit
€-19k
- 22-24
Cash flow
€7k
-90.0% 22-24
Total assets
€450k
+6.0% 22-24
Equity
€32k
-37.0% 22-24
Working capital
€-17k
- 22-24
Income taxes
€460
-95.9% 22-24
Debt
€418k
+11.8% 22-24
Debt ≤ 1y
€64k
-10.9% 22-24
Debt > 1y
€354k
+17.2% 22-24
Current ratio
0.74
-38.1% 22-24
Quick ratio
0.64
-46.8% 22-24
Solvency
7.1%
-40.6% 22-24
Debt / equity
13.15
+77.6% 22-24
ROE
-58.8%
- 22-24
ROA
-4.2%
- 22-24
Interest coverage
1.66
-88.1% 22-24
Figures by fiscal year
Fiscal year2024
Revenue-
EBITDA€19k
Net profit€-19k
Cash flow€7k
Staff costs-
Income taxes€460
Dividends-
Total assets€450k
Equity€32k
Debt€418k
of which ≤ 1y€64k
of which > 1y€354k
Working capital€-17k
Employees (FTE)-
Ratios (computed)
2024
Current ratio0.74
Quick ratio0.64
Working capital ratio-3.7%
Solvency7.1%
Debt / equity13.15
Long-term debt ratio11.15
Interest coverage1.66
Gross margin-
Net margin-
ROA-4.2%
ROE-58.8%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€450k
Fixed assets 21/28€403k
Tangible fixed assets 22/27€403k
Current assets 29/58€47k
Stocks & contracts in progress 3€7k
Amounts receivable within one year 40/41€17k
Cash & bank 54/58€15k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€450k
Equity 10/15€32k
Contributions / capital 10/11€5k
Reserves 13€27k
Amounts payable 17/49€418k
Amounts payable after one year 17€354k
Amounts payable within one year 42/48€64k
Trade debts payable within one year 44€16k
Income statement
Gross operating margin 9900€47k
Operating result 9901€-7k
Financial income 75€167
Financial charges 65€11k
Result before taxes 9903€-18k
Income taxes 67/77€460
Net result for the period 9904€-19k
Result to be appropriated 9905€-19k
You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
20 / 100 Critical
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.

Structure & network

Locations & real estate

Establishment units

2 locations
Sharp Kinesitherapie
Liersesteenweg 6/8, 2547 LintSport- en recreatieonderwijs
since 20212.316.688.018
Sharp Kinesitherapie
Kiliaanstraat 22-24, 2570 DuffelSport- en recreatieonderwijs
since 20252.376.812.180
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels2
Ground area1,479 m²
Buildings2
Building footprint648 m²
Volume (LiDAR)3,566 m³
Tallest building12.1 m · ±1 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 2 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
12009A0619/00F000 Flanders 802 m² 1 · 222 m² 12.1 m · 1 fl.
11025D0423/00F002 Flanders 677 m² 1 · 426 m² 11.7 m · 1 fl.
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Analysis

Snowflake analysis

financial profile on 5 axes
Health20Profitability0Solvency10Growth52Stability94
35 / 100

Fragile profile, watch profitability in particular.

Health 20
Profitability 0
Solvency 10
Growth 52
Stability 94

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, ranked by comparable size

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Ambulante revalidatieactiviteiten86905Activiteiten op het gebied van kinesitherapie86951
Primary activity highlighted.
Names & trade names
Legal nameNL Sharp Kinesitherapie
Registered office
Liersesteenweg 6/8
2547 Lint, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.